Bubendorf, Switzerland, Thursday, April 25, 2019 – In a new research program the surface of PEEK medical implants will modified to enhance osteointegration and soft-tissue compatibility. The modification is targeting the use of PEEK at the at the hard-to-soft-tissue interface such as in dental applications. PEEK or Poly-ether-ether-ketone has been used as an implant material in craniofacial application for several years. Implants made from the material have a high thermal stability and chemical resistance, good mechanical properties close to the human bone and good biocompatibility causing neither toxic, mutagenic effects nor significant inflammation. The major drawback is its relative hydrophobic surface that is not favorable for protein absorption leading to reduced cellular adhesion.

About CIS Pharma Biomaterials

CIS Pharma has developed a platform of proprietary polymers, including a toolki, to create biomaterials specific to their application and site of use. The platform polymers are applicable in the fields of nanotechnology, diagnostics and biomedicine. Tissue regeneration, lab-on-a-chip assays and scaffolds releasing active agents are targeted applications. Novel polymer structures offer contact points for conjugation and delivery of therapeutics. The structures are adapted to fit the chemical and physical properties of the therapeutics and the site of delivery. Conjugated active compounds comprise small molecules as well as large protein-based drugs. Specific linker chemistry is applied to control the release kinetics of conjugated therapeutics.

Both the platform monomers as well as polymers show excellent biocompatibility, superior to commonly used building blocks in the implant industry. The safety of our building blocks has been demonstrated in cytotoxicity and genetoxicity models.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of therapeutics that are the standard of care, thereby improving patient’s experience and treatment outcome. Medical need, patient centricity and digital technology are key to our research and development programs. CIS Pharma is located in the region of Basel, Switzerland, one of the most successful life sciences locations in the world. For more information about the company, visit our website www.cis-pharma.com.